There are eight types of herpes viruses, and despite the fact that most people think of herpes as a sexually transmitted disease, they are mostly passed on via saliva in childhood. Read More

Founded in November 2010, Radebeul, Germany-based biocrea GmbH hopes to be able to make its mark in the midst of what CEO Thomas Kronbach called a "tectonic event" – big pharma's retrenchment from central nervous system (CNS) diseases. Read More

Pfizer Inc., of New York, extended its tender offer for King Pharmaceuticals Inc., of Bristol, Tenn., to Jan. 28, 2011. Pfizer agreed to buy King in October for $14.25 per share, or about $3.6 billion. Read More

Chelsea Therapeutics International Ltd., of Charlotte, N.C., reported new 12-month data from Study 303, a safety extension study from its Phase III Northera (droxidopa) registration program in symptomatic neurogenic orthostatic hypotension (NOH). Read More

Researchers from the University of Georgia and Emory University have shown that T cells bind to antigens and major histocompatibility complex molecules in a tightly controlled two-step sequence, rather than simultaneously. Read More

In what could be a positive sign for the market, both Pharmasset Inc. and Corcept Therapeutics Inc. priced public offerings Friday at only slight discounts. Better yet, shares of both firms traded up despite the dilution. Read More

A week after Vivus Inc. CEO Leland Wilson praised the FDA during a breakout session at the J.P. Morgan Healthcare conference, the agency's request for more data about the incidence of birth defects in children born to women using topiramate, a component in obesity treatment Qnexa (phentermine/topiramate), shook the company's stock and plans for August FDA approval and a late 2011 launch. Read More